MONTREAL, Nov. 24, 2004 (PRIMEZONE) -- Viropro Pharma, a subsidiary of Viropro Inc. (OTCBB:VPRO) is pleased to announce the nomination of Dr. Jean-Louis Boitieux, internationally renowned expert in the field of immunology, to its scientific advisory board. Dr. Boitieux is a university professor and Research Director at the prestigious INSERM in France (Institut National de la Sante et de la Recherche Medical).
Viropro Pharma specializes in international business development through the creation of partnerships and the commercialization of technology, along with proven and innovative products in the field of life sciences.
Dr. Jean-Louis Boitieux holds two doctorates in biology from the Universite des sciences et de la technologie de Compiegne, France and has received training in both Arizona and Kansas universities in the United States. Dr. Jean-Louis Boitieux is noted as a pioneer and specialist in the field of immunology and antibody procedures in the recognition of cancerous cells. He is the author of over 100 medical publications and holds a number of patents. As the former scientific advisor to the Ambassador of France in Canada, he continues to pursue his career as the French delegate for science and technology at the European Union in Brussels and is a member of the New York Academy of Sciences in the United States. The French Government has recently honored him with the medaille de l'ordre national du merite de France in recognition of his scientific achievements.
"We are honored to have an internationally renowned expert such as Dr. Jean-Louis Boitieux sit on our committee to help ensure that our technology and products are adapted to the needs of our targeted international markets," says Serge Beausoleil, President of Viropro Pharma. "Our scientific advisory committee will provide the expert opinion and technical support related to the identification and validation of new technology as well as overseeing the implementation of technology transfers."
The recent creation of Viropro Pharma's scientific committee aims to unite the expertise and know-how of international leaders. In the following weeks, several other nominations of equal caliber will be added to help reinforce and strengthen the committee's expertise.
About Viropro
Viropro, Inc. (OTCBB:VPRO) is seeking to establish a growth portfolio in Life Sciences markets through strategic alliances and revenue-producing acquisitions with the potential for continued shareholder value.
Viropro, Inc.'s Safe Harbor Statement
Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward looking statements." Forward looking statements in this release may be identified through the use of such words as "expects," "anticipates," "estimates," "believes," or statements indicating certain actions "may," "could," or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.